Frazier Life Sciences Management, L.P. Savara Inc Transaction History
Frazier Life Sciences Management, L.P.
- $1.86 Billion
- Q3 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Savara Inc stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 8,157,385 shares of SVRA stock, worth $25.5 Million. This represents 1.86% of its overall portfolio holdings.
Number of Shares
8,157,385
Previous 8,157,385
-0.0%
Holding current value
$25.5 Million
Previous $32.9 Million
5.21%
% of portfolio
1.86%
Previous 1.94%
Shares
2 transactions
Others Institutions Holding SVRA
# of Institutions
129Shares Held
158MCall Options Held
67.6KPut Options Held
29.4K-
Nea Management Company, LLC Timonium, MD24.5MShares$76.6 Million7.93% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA14.6MShares$45.6 Million11.08% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$38.7 Million6.8% of portfolio
-
Wellington Management Group LLP Boston, MA8.62MShares$27 Million0.01% of portfolio
-
Vestal Point Capital, LP New York, NY8.09MShares$25.3 Million2.6% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $357M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.